Curasight
HC Andersen Capital receives payment from Curasight for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreLatest research
Analyst
![Henrik Ekman Henrik Ekman](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/6e03ef5d-f5bb-4113-a20b-1a7d036027c4.png)
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Forum updates
Curasight: Directed issues registered at the Danish Business Authority
![Dagens aktienyheder 27/6: Curasight, Danske Bank og Boozt](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/c3c80b39-95a4-440a-bffc-88d879568282.png)
Dagens aktienyheder 27/6: Curasight, Danske Bank og Boozt
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
![Curasight: Management remains confident on its strategy as new financing plan is launched](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/b1071161-b901-4fc5-ae33-33cc74450ee6.png)
Curasight: Management remains confident on its strategy as new financing plan is launched
![Curasight – Opdatering af strategien efter seneste kapitalforhøjelse](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/b1071161-b901-4fc5-ae33-33cc74450ee6.png)
Curasight – Opdatering af strategien efter seneste kapitalforhøjelse
BioStock: Curasight CEO comments on capital raise and milestone
Curasight to present at HC Andersen Capital
![Dagens aktienyheder 18/6: Sparekassen Sjælland-Fyn, BioPorto A/S og Curasight](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/e1c59d72-1d71-4407-82fa-75ff3acd902b.png)
Dagens aktienyheder 18/6: Sparekassen Sjælland-Fyn, BioPorto A/S og Curasight
Curasight: Notice of Extraordinary General Meeting
![Dagens aktienyheder 17/6: TORM og Curasight](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/7d7aaddb-6f1e-4803-ad22-e7a6b2d0a9bb.png)
Dagens aktienyheder 17/6: TORM og Curasight
Curasight A/S resolves on directed issues and a loan facility
![Dagens aktienyheder 12/6: Asetek, Curasight og Scandinavian Medical Solutions](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/053fb40e-3666-4e35-9f86-f3c921338f50.png)
Dagens aktienyheder 12/6: Asetek, Curasight og Scandinavian Medical Solutions
Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer
BioStock: Curasight committed to progressing pipeline
Redeye: Curasight Q1 - Moving forward
![Dagens aktienyheder 24/05: Curasight, Impero og MapsPeople](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/e15ece25-e043-4e21-b7c4-74fd5f5eb8bb.png)
Dagens aktienyheder 24/05: Curasight, Impero og MapsPeople
![Dagens aktienyheder 23/05: MapsPeople, Penneo, Audientes, Curasight og Skako](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/f36b1e0e-d9cf-4c1e-87b5-c02b76428a15.png)
Dagens aktienyheder 23/05: MapsPeople, Penneo, Audientes, Curasight og Skako
Curasight: Interim report Q1 2024
BioStock: Curasight gets green light from EMA in phase II prostate cancer trial
![Dagens aktienyheder 17/04: Gubra Netcompany, Scandinavian Medical Solutions, ExpreS2ion Biotechnologies og Curasight](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/84ea8977-34ae-494d-9866-d121ccc33e06.png)